Request Demo

Last update 21 Oct 2026

Acetaminophen

Last update 21 Oct 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryParacetamol, known by its alternate name acetaminophen, is a common analgesic and antipyretic used to reduce fever and alleviate pain. Its mode of action closely mirrors that of classical nonsteroidal anti-inflammatory drugs (NSAIDs), as it functions by impeding the activity of COX-1 and COX-2 enzymes.Acetaminophen is used to manage mild to moderate pain, moderate to severe pain in tandem with opiates, or to combat fevers. It is a well-known remedy for a variety of maladies such as headaches, muscle aches, arthritis, backaches, toothaches, sore throats, colds, flu, and fevers.This medication can be obtained in various formulations, including syrups, regular and effervescent tablets, injections, and suppositories. Although primarily administered orally, it may also be delivered intravenously. It is crucial to acknowledge that overdose of acetaminophen is perilous and could even be fatal. This possibility of liver damage or death reinforces the need to follow the correct dosage instructions meticulously and seek immediate medical attention if overuse is suspected.Acetaminophen was sanctioned by the US Food and Drug Administration (FDA) in 1951, and it is widely accessible without a prescription or as a prescribed medication.

Drug Type

Small molecule drug

Synonyms

4'-hydroxyacetanilide, 4-(Acetylamino)phenol, 4-ACETAMIDOPHENOL

+ [93]

Target

COXs

Action

inhibitors

Mechanism

COX inhibitors(Cyclooxygenases inhibitors)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesNervous System Diseases+ [5]

Active Indication

EaracheHeadacheInfluenza, Human+ [9]

Inactive Indication

Acute migraineAcute PainAnesthesia+ [21]

Originator Organization

Dandong Yichang Pharmaceutical Co., Ltd.

Active Organization

Fresenius Kabi USA LLC

Terumo Corp.

Adiramedica LLC

+ [15]

Inactive Organization

Cosette Pharmaceuticals, Inc.

GSK Plc

Keenova Therapeutics Plc

+ [21]

License Organization

Seelos Therapeutics, Inc.

Ligand Pharmaceuticals, Inc.

Essex Bio-Technology Ltd.

+ [2]

Drug Highest PhaseApproved

First Approval Date

China (01 Jan 1966),

FeverPain

Regulation-

Structure/Sequence

Molecular FormulaC8H9NO2

InChIKeyRZVAJINKPMORJF-UHFFFAOYSA-N

CAS Registry103-90-2

1,840

Clinical Trials associated with Acetaminophen

NCT07870278

/ Not yet recruitingPhase 1

A Phase 1 Open-label Study to Evaluate the Safety and Efficacy of MK-6255 Monotherapy in Advanced Solid Tumors

Researchers are looking for new ways to treat advanced and recurrent endometrial cancer (EC) and ovarian cancer (OC). Advanced means the cancer has spread to other parts of the body and cannot be removed with surgery. Recurrent means the cancer came back after treatment.
MK-6255 is a trial medicine designed to treat advanced and recurrent EC and OC. This trial is the first time that researchers will give MK-6255 to people.
The goals of this trial are to learn about:
* The safety of MK-6255 and if participants tolerate it. Tolerate means participants will receive the trial medicine unless they need to stop it due to health problems.
* What happens to different dose levels (amounts) of MK-6255 in the body over time.

Start Date13 Nov 2026

Sponsor / Collaborator

Merck Sharp & Dohme LLC

NCT07855588

/ Not yet recruitingPhase 4IIT

Intravenous Paracetamol Versus Magnesium Sulfate for Control of Shivering Following Spinal Anesthesia in Cesarean Section: A Comparative Study

Spinal anesthesia is widely used for cesarean deliveries, but shivering is a frequent complication that occurs in 40% to 60% of patients. Post-spinal shivering can cause maternal discomfort, increase oxygen consumption and metabolic demands, and interfere with clinical monitoring. Both paracetamol and magnesium sulfate have thermoregulatory properties that may prevent or reduce shivering.
The purpose of this clinical trial is to compare the efficacy and safety of intravenous paracetamol versus intravenous magnesium sulfate in preventing and reducing shivering following spinal anesthesia in women undergoing elective cesarean section.
A total of 90 pregnant women scheduled for elective cesarean delivery will be randomly assigned to one of two groups:
* Group P (Paracetamol Group): Participants receive intravenous paracetamol (15 mg/kg) infused over 15 minutes immediately following the subarachnoid block.
* Group M (Magnesium Sulfate Group): Participants receive intravenous magnesium sulfate (30 mg/kg) administered immediately following the subarachnoid block.
The primary outcome evaluated is the severity of post-spinal shivering assessed by shivering scores. Secondary outcomes include hemodynamic parameters (heart rate, blood pressure, oxygen saturation), postoperative pain, complications such as nausea and vomiting, and maternal satisfaction.

Start Date01 Nov 2026

Sponsor / Collaborator

Assiut University

NCT07595302

/ Not yet recruitingPhase 4IIT

Comparing Pain Improvement for Intravenous Versus Oral Acetaminophen in Acute Pelvic Pain: A Randomized, Double-Blind, Double-Dummy Controlled Trial (PIVOTAL Trial)

The investigator team proposes a randomized, double-blind, double-dummy comparative effectiveness trial conducted in two urban emergency departments (EDs) in the Bronx, New York. This study is designed to determine the relative efficacy of IV acetaminophen compared to PO acetaminophen in treating pelvic pain. This design focuses on the early onset of action and short-term efficacy, which may better capture potential differences between IV and PO acetaminophen in the acute ED setting.

Start Date01 Nov 2026

Sponsor / Collaborator

Montefiore Medical Center

100 Clinical Results associated with Acetaminophen

100 Translational Medicine associated with Acetaminophen

100 Patents (Medical) associated with Acetaminophen

44,026

Literatures (Medical) associated with Acetaminophen

01 Feb 2027·TALANTA

Ternary signal amplification platform based on β-CD/NADH/MoS2 for ultrasensitive detection of acetaminophen in human serum by CV/DPV dual-signal

Article

Author: Feng, Xiao-Zhen ; Lyu, Jia-Qi ; Han, Guo-Cheng ; Chen, Shu-Hui ; Qin, Yuejia

Accurate detection of acetaminophen (AP) in human serum is essential to ensure clinical safety. Herein, an electrochemical detection platform was developed by modifying a glassy carbon electrode (GCE) with β-CD, NADH, and MoS₂, which produced triple synergistic signal amplification to achieve a nearly 2-fold cooperative amplification effect. The modification process of β-CD/NADH/MoS₂/GCE was systematically verified by SEM, XPS, FT-IR and BET. The electrooxidation of AP on the electrode was confirmed to involve 2 electrons and 2 protons via density functional theory (DFT) calculations. Evaluated by cyclic voltammetry (CV) and differential pulse voltammetry (DPV), the platform exhibited an ultra-wide linear range (1.00-3000.00 μM), an extremely low limit of detection (100.00 nM), excellent stability and anti-interference ability. Its recovery rate in actual serum samples was 92.14%-106.19%, showing superior detection performance to UV-Vis spectroscopy and fluorescence methods, and this simple, low-cost platform has significant practical value for clinical AP detection.

01 Feb 2027·TALANTA

Influence of graphene-based ink formulation on the performance of inkjet-printed electrochemical sensors for detecting water contaminants of emerging concern

Article

Author: Melendi-Espina, Sonia ; González, Zoraida ; Quintana, Lucía ; Granda, Marcos ; Álvarez, Patricia ; Dowding, Colin F ; Menéndez, Rosa

Inkjet printing has emerged as a promising approach for the fabrication of low-cost and scalable electrochemical sensors, particularly when carbon-based nanomaterials are used. This study investigates the influence of graphene-based ink formulation on the performance of inkjet-printed sensors designed for the detection of acetaminophen, a pharmaceutical product identified as a water contaminant of emerging concern. Two ink formulations were prepared, each containing an aqueous graphene oxide suspension as the functional material, Triton X-100 as a surfactant, and carbon black as a conductive additive. However, they differed in their solvent systems, with the aim of optimising both, ink printability and the electrochemical response of the resulting sensors. The printed electrodes' morphology, pattern topography/uniformity, electrical conductivity, surface chemistry and electrochemical performance toward target analyte were characterized. Our findings reveal that ink composition significantly impacts film uniformity, electron transfer kinetics, and overall sensor performance. The formulation incorporating a mixed solvent system (water, glycerol, ethylene glycol) exhibited superior performance, achieving lower detection limits (LOD ∼ 0.572 μM) and enhanced reproducibility and repeatability (% RSD ∼ 5.3 and 5.7, respectively) for acetaminophen sensing. These results highlight that rational ink formulation is not merely an optimization parameter, but a decisive design factor that markedly influences the performance of printed electrochemical sensors, establishing it as a critical element for advancing reliable and high-impact environmental monitoring technologies.

01 Jan 2027·WATER RESEARCH

In-Situ engineering of hierarchical ZIF@HOF heterostructures for efficient antibiotic degradation: Mechanistic insights from experimental and DFT studies

Article

Author: Yu, Bing ; Ahmad, Ali ; Tufail, Muhammad Khurram ; Cong, Hailin ; Akram, Naeem

The relentless release of pharmaceutical antibiotics into water bodies demands robust and reusable photocatalysts. Herein, a hierarchical ZIF-67@Co-HOF-x heterostructure is synthesized through the in-situ growth of ZIF-67 onto a pre-formed cobalt-based hydrogen-bonded organic framework (Co-HOF). Among the series, ZIF-67@Co-HOF-200 exhibits uniform dispersion, intimate interfacial contact, and enhanced charge separation, as demonstrated by XRD, FTIR, SEM-EDS, TEM, XPS, PL, EIS, and TGA analyses. DFT calculations further reveal strong interfacial electronic coupling, with CDD, ELF, and Bader analyses confirming charge redistribution across the ZIF-67/Co-HOF interface. Compared with pristine components, the heterostructure exhibits enhanced visible-light absorption with a narrowed band gap of 2.01 eV, suppressed photoluminescence, and reduced charge-transfer resistance. Under optimized conditions (pH 7, catalyst dosage 0.5 g L⁻¹, and initial TCH concentration of 20 ppm), ZIF-67@Co-HOF-200 achieves 98% TCH degradation within 60 min following pseudo-first-order kinetics (k = 0.06,144 min⁻¹). The catalyst also demonstrates excellent versatility toward paracetamol, methyl orange, and Congo red, while maintaining 79% TCH removal efficiency under simulated wastewater conditions. Molecular interaction calculations further reveal favorable TCH and O₂ accessibility at the heterointerface, supporting efficient pollutant degradation and ROS generation. The catalyst retains 94% of its initial activity after four consecutive cycles, demonstrating excellent stability. Mechanistic investigations identify O₂•⁻ and h⁺ as dominant reactive species during degradation. This work provides a rational strategy for constructing MOF/HOF heterostructures with enhanced interfacial charge regulation for visible-light-driven wastewater remediation.

805

News (Medical) associated with Acetaminophen

20 Oct 2026

·www.prnewswire.com

First joint guidelines of care for hidradenitis suppurativa issued by American Academy of Dermatology and Hidradenitis Suppurativa Foundation

ROSEMONT, Ill., Oct. 20, 2026 /PRNewswire/ -- Over 3 million people have been diagnosed with hidradenitis suppurativa (HS) in the United States and today, the American Academy of Dermatology (AAD) and the Hidradenitis Suppurativa Foundation (HSF) have published the first-ever joint guidelines for the management and care of HS. HS is a skin condition that causes painful lumps deep in the skin, typically in areas of the body where skin rubs together like armpits, inner thighs, and the groin. Early diagnosis of HS is critical as it is often confused with acne or infection, causing people to go years without an accurate diagnosis. A board-certified dermatologist can both identify HS and screen for the medical and psychiatric conditions that often accompany it, giving patients access to comprehensive, individualized care sooner. "While hidradenitis suppurativa is a chronic condition, its painful symptoms are highly treatable," said AAD President and board-certified dermatologist Murad Alam, MD, MSCI, MBA, FAAD. "For millions of people with HS, dermatologists provide more than just a diagnosis. They provide expert, comprehensive care that allows patients to have a better quality of life." Compiled by a work group of 13 experts, including 12 board-certified dermatologists, the newly released guidelines, published in the Journal of the American Academy of Dermatology (JAAD), include 37 evidence-based recommendations designed to treat chronic HS disease and acute HS flares. "These guidelines establish an evidence-based standard of care for HS, giving patients, dermatologists, and payers a shared roadmap for what high-quality HS care looks like," said board-certified dermatologist Haley B. Naik, MD, FAAD, co-chair of the Hidradenitis Suppurativa Guideline Work Group and president of HSF. "Every person living with HS deserves care that meets this standard." The largest barrier to impactful HS care is step therapy, an insurance requirement for patients to try insurer-designated treatments before coverage is approved for the dermatologist-prescribed preferred medication. Evidence does not support the use of step therapy in HS care as it delays access to appropriate treatment. Strong recommendations of care Strong recommendations imply that treatment benefits clearly outweigh risks and burdens. These recommendations apply to most patients in most circumstances. Biologics (adalimumab, bimekizumab, infliximab, and secukinumab), injectable treatments that target the immune system, are strongly recommended for individuals with moderate-to-severe HS. These treatments are shown to reduce the number of abscesses and nodules by at least half, without any new abscess or tunnel development. Abscesses are painful lumps that grow, join together, and fill with fluid. Tunnels are hollow channels that form under the skin. Conditional recommendations of care Conditional recommendations imply that treatment benefits are closely balanced with risks and burdens. These recommendations apply to most patients, but the best course depends on what matters most to each individual, including their tolerance for side effects, treatment goals, and day-to-day circumstances. Topical therapies (clindamycin, resorcinol, and ruxolitinib) are applied to the skin to reduce abscesses and the severity of symptoms. Systemic antibiotics (doxycycline, tetracycline, clindamycin in combination with rifampin, and ertapenem) work throughout the body to decrease severity of symptoms and improve quality of life. Hormone therapy (spironolactone) is taken by mouth to decrease severity. Systemic therapies (upadacitinib and short-term systemic steroids) are taken by mouth and work throughout the body for individuals with moderate-to-severe HS to reduce disease activity and pain. Continuing injectable biologics (adalimumab) is recommended for individuals with moderate-to-severe HS undergoing surgery. In-office procedures can be especially helpful if abscesses and tunnels have formed in the skin, including: Deroofing, a minor treatment to open and flatten the tunnels under the skin. This treats recurrent or persistently bothersome HS lesions, or bumps, spots, or growths. Incision and drainage to treat painful abscesses. Surgical removal of an area of affected skin for abscesses or tunnels that persist or continue to come back. Laser hair removal for fewer flares. Botulinum toxin to reduce flares. Intralesional triamcinolone (a steroid injection) to treat painful, flaring bumps. Conditional recommendations were made against the use of oral retinoids (acitretin and isotretinoin), certain biologics (etanercept, guselkumab, risankizumab, and vilobelimab), systemic therapies (avacopan, and methotrexate and azathioprine as primary treatments), and radiotherapy for pediatric and adolescent HS patients. In addition, there is insufficient evidence to support oral contraceptive pills or finasteride (hair loss medication) for HS management. Supportive management While HS therapies may reduce pain, they don't always achieve adequate pain relief. Supportive pain management is a conditional recommendation that helps manage sudden pain, consistent pain, and pain that does not improve after treatment and pain relief therapies. Treatments to manage sudden pain include warm or cool compresses, topical lidocaine (a local anesthetic), acetaminophen (a pain reliever), nonsteroidal anti-inflammatory drugs like aspirin and ibuprofen, steroid injections, incision and drainage, and short-term steroids that work throughout the body. Opioids can be used if the pain doesn't decrease through other treatments. Long-lasting pain can be managed with serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, psychotherapy, proper wound care, and nerve pain medications such as gabapentin and pregabalin. There is insufficient evidence to support weight reduction and GLP-1 usage for HS treatment. There is also insufficient evidence that specific diet plans — intermittent fasting, the Mediterranean diet, the yeast exclusion diet, and the dairy-free diet — help manage HS. However, a heart-healthy diet of fruits and vegetables, whole grains, healthy fats, and lean proteins remains important for reducing heart and diabetes risk for individuals with HS. Complementary medicine Lifestyle changes and supplements can also help manage the pain and discomfort from HS. A conditional recommendation was made for quitting tobacco, which can improve an individual's response to treatments aimed at addressing the disease itself. Conditional recommendations were made for complementary and alternative medicine, including vitamin D supplements for individuals with deficiencies, and zinc supplements. These supplements, taken under a doctor's supervision, may reduce lumps and tunnels and relieve pain. "Untreated HS can have a serious impact on your health and well-being. It can cause scarring, wounds that limit your mobility, and intense pain. It also often happens in combination with other medical and psychiatric conditions, with this increasing its overall toll on patients," said Dr. Alam. "Whether you've been diagnosed with HS or suspect you may have it, please take the time to see a board-certified dermatologist to have it expertly assessed, consider your options, and find the best plan for you." To find a board-certified dermatologist in your area, visit aad.org/findaderm. Resources Hidradenitis Suppurativa: Overview (AAD) How to Treat HS (HSF) Find an HS Provider (HSF) About the AAD Headquartered in Rosemont, Ill., the American Academy of Dermatology, founded in 1938, is the largest, most influential and most representative of all dermatologic associations. With a membership of more than 21,500 physicians worldwide, the AAD is committed to advancing the diagnosis and medical, surgical, and cosmetic treatment of the skin, hair, and nails; advocating high standards in clinical practice, education and research in dermatology; and supporting and enhancing patient care because skin, hair, and nail conditions can have a serious impact on your health and well-being. For more information, contact the AAD at (888) 462-DERM (3376) or aad.org. Follow @AADskin on Facebook, TikTok, Pinterest, and YouTube, and @AADskin1 on Instagram. About the Hidradenitis Suppurativa Foundation Since its founding in 2005, the Hidradenitis Suppurativa Foundation has fostered and encouraged worldwide research by developing and supporting an interdisciplinary family of scientists and physicians devoted to studying Hidradenitis Suppurativa, in order to deliver more effective forms of treatment and preventative measures to those with this common, debilitating, and eminently chronic disease. HSF is a 501(c)(3) dedicated to improving the lives of people affected by Hidradenitis Suppurativa (HS) through research, education, and advocacy. Explore their resources for patients, clinicians, and investigators at hs-foundation.org, and follow @hsforg on Instagram and YouTube, and @HidradenitisSuppurativaFoundation on Facebook and LinkedIn. SOURCE American Academy of Dermatology 21% more press release views with Request a Demo

16 Oct 2026

·www.opella.com

Press Release. Opella and World Allergy Organization launch five-year partnership to improve allergy care for millions worldwide.

Deep dive. Kyoto, Japan - 16 October 2026 - Opella, a global leader in consumer healthcare, and the World Allergy Organization (WAO), a worldwide federation of allergy and clinical immunology societies working to enhance global allergy education, today announced a five-year global partnership to improve how allergic diseases are recognized and managed in everyday care settings around the world. Running from 2027 through 2031, the partnership brings together expertise within the WAO global network of allergy societies with Opella's scientific expertise and leadership in self-care to support the clinicians who manage allergic disease most often: general practitioners, pediatricians, pharmacists, nurses and primary care teams. The announcement was made at the 32nd World Allergy Congress (WAC) in Kyoto, Japan where the two organizations also unveiled the first WAO-Opella Award for Innovative Solutions in Everyday Allergy Care. Opella and WAO will also collaborate on their first joint ‘Self-care in Allergy Report’ in December this year, shining a spotlight on the need for stronger awareness, earlier action and better support for people living with allergies. A key focus of the collaboration will be helping drive earlier recognition of allergic disease, support best-practice management, and spotlight innovative approaches that improve patient outcomes in everyday clinical settings. The new award will celebrate measurable improvements in how allergic disease is recognized and managed at this frontline level of care. The inaugural cycle will focus on care for children and adolescents, reflecting the significant and often under-recognized impact of allergic disease on sleep, school attendance and daily life. Entries will open in January 2027, with inaugural winners to be announced in mid-2027 and presented at the World Allergy Congress in October 2027. Allergic diseases affect a substantial and growing proportion of the global population, with a particularly important burden in children and adolescents. Allergic rhinitis alone affects hundreds of millions of people worldwide1 and remains frequently underdiagnosed and undertreated. Its impact extends well beyond symptoms, affecting sleep, school and work performance, wellbeing and quality of life. Earlier recognition, appropriate self-care, timely professional advice and clear referral pathways can help improve outcomes and reduce the broader burden of allergic disease.2 Dr. Josephine Fubara, Chief Science Officer of Opella. Healthcare professionals and pharmacists are often the first point of care for millions of people living with allergies. This new partnership combines Opella’s expertise in self-care with WAO’s scientific leadership to help advance allergy care globally. Through peer-to-peer healthcare professional engagement, education and health literacy initiatives, and the development of evidence-based allergy resources and care pathways, we aim to put health in people’s hands and give them the knowledge and resources they need to manage their allergies and health with confidence. Prof. Mário Morais-Almeida, President of the World Allergy Organization. Allergic diseases are often first recognized and managed far from the allergist's office – in primary care, pediatrics, pharmacies and community settings. The quality of that first interaction can shape the entire patient journey. This partnership will help bring evidence-based, WAO-endorsed guidance closer to the professionals who see these patients every day, while recognizing their essential role in patient-centered care and helping reduce gaps in access to high-quality allergy care worldwide. WAO will invite its global network of allergy societies to promote and participate in the partnership, alongside engagement with international key opinion leaders, with further details on upcoming health literacy programs and frontline initiatives to be shared in the months ahead. About Opella. Opella is the self-care challenger with the purest and third-largest portfolio in the Over-The-Counter (OTC) & Vitamins, Minerals & Supplements (VMS) market globally. Our mission is to bring health in people’s hands by making self-care as simple as it should be. For half a billion consumers worldwide – and counting. At the core of this mission is our 100 loved brands, our 11,000-strong global team, our 13 best-in-class manufacturing sites and 4 specialized science and innovation development centers. Headquartered in France, Opella is the proud maker of many of the world’s most loved brands, including Allegra, Buscopan, Doliprane, Dulcolax, Enterogermina, Essentiale and Mucosolvan. Opella is a certified B Corporation™, reflecting its commitment to high standards of social and environmental performance. Find out more about our mission at www.opella.com. About World Allergy Organization (WAO). World Allergy Organization (WAO) is a federation of 116 regional and national allergology and clinical immunology societies from around the world. By collaborating with its member societies, WAO provides educational programs, symposia, and lectureships to individual members in nearly 100 countries. Founded in 1951, WAO has successfully organized over 30 major congresses. Our mission, as a worldwide alliance of allergy/immunology societies, is to be a global resource and advocate for the specialty, while advancing awareness and excellence in clinical care through education, research, and training. Visit their website to learn more at www.worldallergy.org. Press Contacts. Justine Rohée. justine.rohee@opella.com. +33 6 86 47 85 60. Philippa Carnohan. philippa.carnohan@opella.com. +33 6 31 14 82 36. All trademarks mentioned in this press release are the property of Opella. pdf version.

11 Oct 2026

·www.sciencedaily.com

Eating olive oil before carbs has a surprising effect on blood sugar

A simple change in the order you eat your food could help prevent blood sugar spikes. Scientists discovered that giving mice olive oil before carbohydrates slowed digestion and activated a surprising combination of hormones and nerve signals that helped regulate blood sugar, even in mice with type 2 diabetes.The order in which you eat different foods may have a surprising effect on blood sugar levels. Research in mice suggests that consuming fat before carbohydrates can reduce the sharp rise in blood sugar that typically follows a meal. The findings also reveal how hormones and nerve signals work together to influence this response. Keeping blood sugar from rising too high after eating is an important part of diabetes management. Previous clinical studies have shown that eating vegetables, protein, or fat before carbohydrates can help limit these increases. This suggests that changing the sequence of foods during a meal could offer a practical, sustainable way to improve blood sugar control without eliminating entire food groups. Scientists have generally explained this effect through two main mechanisms. The first is slower gastric emptying, which means food moves from the stomach into the small intestine more gradually. The second involves increased release of hormones called incretins, including GLP-1, which help the body regulate blood sugar. However, researchers have not fully understood how hormones produced by the gut and pancreas interact with the nervous system to produce these effects. To investigate, an international research team examined how consuming fat before or after glucose influences blood sugar, hormone activity, and the speed at which the stomach empties. "Our group has long been interested in practical dietary approaches that people can continue in everyday life," says corresponding author Daisuke Yabe of Kyoto University. "Meal-sequencing is appealing because it merely changes how a meal is eaten rather than requiring people to avoid entire food groups." Testing How Olive Oil Changes Blood Sugar Levels The researchers conducted a series of experiments in mice to determine whether the timing of fat consumption affected how the body processed glucose. After an overnight fast, the mice were assigned to three groups. One group received water followed by glucose. A second group was given olive oil, followed 15 minutes later by glucose. The third group received glucose first, with olive oil administered 15 minutes afterward. The scientists then measured blood glucose levels and several hormones involved in blood sugar regulation, including insulin, glucagon, GIP, and GLP-1. Glucagon is normally associated with increasing blood sugar, while GIP and GLP-1 help regulate glucose levels after eating. To determine how quickly material was leaving the stomach, the researchers also administered acetaminophen, a common pain reliever. By measuring how much of the drug appeared in the bloodstream after oral administration, they could estimate the rate of gastric emptying. The team extended the experiments to additional groups of mice, including animals with type 2 diabetes and others that lacked the receptor needed to respond to GLP-1. They also performed experiments that blocked glucagon or GLP-1 signaling, surgically interrupted the vagus nerves below the diaphragm on both sides, and examined whether different dietary fats produced similar results. The vagus nerve is an important communication pathway between the brain and digestive system, helping coordinate functions such as digestion and hormone release. Eating Fat First Slows Blood Sugar Spikes The results showed a clear difference depending on when the mice received olive oil. When olive oil was given before glucose, the initial rise in blood sugar was smaller than when the oil was administered afterward. The earlier fat intake also slowed gastric emptying, delaying the movement of glucose from the stomach into the intestine. At the same time, consuming fat before glucose stimulated an early increase in several hormones, including glucagon, GIP, and GLP-1. Importantly, these effects were also observed in mice with type 2 diabetes and severe insulin deficiency. This suggested that the response could still function even when normal insulin regulation was significantly impaired. A Surprising Role for a Blood Sugar Hormone One of the most unexpected findings involved glucagon, a hormone generally known for raising blood sugar by stimulating the liver to release stored glucose. The researchers discovered that blocking glucagon signaling alone did not eliminate the blood sugar lowering effect of consuming olive oil before glucose. Blocking GLP-1 signaling by itself also failed to remove the benefit. However, when both signaling pathways were blocked simultaneously, the beneficial effect was reduced. This finding suggests that glucagon and GLP-1 work together as part of a more complex system that helps moderate blood sugar after fat is consumed before carbohydrates. It also reveals that glucagon, despite its familiar role in increasing blood sugar, can contribute to a response that ultimately limits the rise in glucose after eating. The vagus nerve experiments provided another important clue. When the researchers interrupted these nerve pathways, the results suggested that communication through the vagus nerve also contributes to the body's response to nutrient order. Together, these findings point to a coordinated interaction between digestive hormones, pancreatic signals, and the nervous system. Could Changing Meal Order Help Manage Diabetes? The findings offer a clearer biological explanation for why eating fat before carbohydrates may help reduce blood sugar spikes. Rather than relying on a single hormone or digestive process, the effect appears to involve multiple systems working together to control how quickly glucose enters the intestine. This could have practical implications for diabetes management. Adjusting the order in which foods are eaten is relatively simple and may be easier to maintain than diets that require avoiding particular food groups. However, the experiments were conducted in mice, and the same effects have not yet been established in humans through this research. Additional clinical studies will be needed to determine whether the mechanisms identified in the experiments can be used to improve blood sugar regulation in people with or without diabetes. "Our findings suggest that the order in which nutrients reach the gut can engage a coordinated hormone-nerve response that changes how quickly the stomach delivers glucose to the intestine," says Yabe.

Clinical Result

100 Deals associated with Acetaminophen

External Link

KEGG	Wiki	ATC	Drug Bank
D00217	Acetaminophen	N02BE01	DB00316

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Earache	Australia	Adiramedica LLC	29 Jun 2026
Influenza, Human	Australia	Adiramedica LLC	29 Jun 2026
Common Cold	Australia	assistpro pharmaceuticals	05 Jun 2026
Dysmenorrhea	Australia	assistpro pharmaceuticals	05 Jun 2026
Migraine Disorders	Australia	assistpro pharmaceuticals	05 Jun 2026
Myalgia	Australia	assistpro pharmaceuticals	05 Jun 2026
Toothache	Australia	assistpro pharmaceuticals	05 Jun 2026
Osteoarthritis	Australia	Nova Pharmaceuticals Australasia Pty Ltd.	10 Apr 2026
Headache	United States	Cosette Pharmaceuticals, Inc.	09 Feb 1978
Analgesia	Japan	Iwaki Seiyaku Co., Ltd.	01 Jul 1966
Fever	China	Dandong Yichang Pharmaceutical Co., Ltd.	01 Jan 1966
Pain	China	Dandong Yichang Pharmaceutical Co., Ltd.	01 Jan 1966

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pharyngitis	Phase 3	-	GSK Plc	01 Feb 2017
Episodic tension-type headache	Phase 3	United States	GSK Plc	01 Apr 2013
Acute Pain	Phase 3	United States	Keenova Therapeutics Plc	01 Jan 2008
Pain, Postoperative	Phase 3	United States	Keenova Therapeutics Plc	01 Nov 2006
Uterine Neoplasms	Phase 3	United States	Keenova Therapeutics Plc	01 Nov 2006
Acute migraine	Phase 3	United States	Merck Sharp & Dohme Corp.	01 Mar 2006
Osteoarthritis, Hip	Phase 3	-	McNeil Consumer & Specialty Pharmaceuticals, Inc.	18 Oct 2005
Diabetic Neuropathies	Phase 3	-	Johnson & Johnson Pharmaceutical Research & Development LLC	01 Dec 2003
Neuropathy, Painful	Phase 3	-	Johnson & Johnson Pharmaceutical Research & Development LLC	01 Dec 2003
Osteoarthritis, Knee	Phase 3	-	Johnson & Johnson Holdco (NA), Inc.	01 Oct 1999

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05548582 (Pubmed \| Obstet Gynecol)	Not Applicable	Pain, Postoperative	64	Acetaminophen, ibuprofen, and 12 5-mg oxycodone tablets	ipzsoouccd(sylkxkqvlm) = ysifzxsebz euaqflzoce (uxtxaosocw ) View more	-	01 Sep 2026
				Acetaminophen and ibuprofen	cdwknpezbs(vcjmsoqlgj) = clvdootxqw qitzcbvcef (kluocmrlim ) View more
NCT04246697 (CTgov)	Phase 4	Analgesia \| Head and Neck Neoplasms	30	Tylenol+Oxycodone+Morphine (Standard of Care A)	hujbrnfvtx(ermxriqeje) = ktqarhmesl bszurioxud (swdltwtanx, 121.4) View more	-	07 Jul 2026
				Tylenol+Oxycodone+toradol+Morphine+Bupivacaine+Gabapentin (Standard of Care B)	hujbrnfvtx(ermxriqeje) = nupuxthlec bszurioxud (swdltwtanx, 100.0) View more
NCT06658574 (CTgov)	Phase 2	Complications of bariatric procedures \| Analgesia \| Pain, Postoperative	65	Acetaminophen (Oral Acetaminophen - Tablet)	ucwqoyacxk(ryndrlihne) = kvftwakskj iphlemdsop (bhwatxyoxs, 1.5) View more	-	06 Jul 2026
				Acetaminophen (Oral Acetaminophen - Liquid)	ucwqoyacxk(ryndrlihne) = tvhipcwisx iphlemdsop (bhwatxyoxs, 1.3) View more
NCT06855576 (CTgov)	Phase 1	Pain \| Fever	54	Panadol film-coated Tablet+Paracetamol ODT (Test Product)	dzvfhttdzo(cautwnnrmz) = nqykkjujtg buxmuofcny (saadsvrvnc, 36.8) View more	-	01 Jul 2026
				Panadol film-coated Tablet+Paracetamol ODT (Reference Product 1)	dzvfhttdzo(cautwnnrmz) = mhcrdhmljm buxmuofcny (saadsvrvnc, 53.6) View more
NCT02417337 (NSAID, CTgov)	Phase 2	Pulpitis \| Pain, Postoperative	185	Paracetamol (Group I)	dzscbmlncs(ttszpcvwjm) = qqrulhdsmn gyppjkmjbj (rvefdeaesr, dtsbbzcqsg - lqrzrsmlua) View more	-	25 Jun 2026
				Paracetamol+Ibuprofen (Group II)	dzscbmlncs(ttszpcvwjm) = dquwrfoqeu gyppjkmjbj (rvefdeaesr, wlyjtfvqhc - kbwomhwpea) View more
NCT05076110 (CTgov)	Phase 4	Pain	86	Oxycodone (Standard of Care Group)	rleqliuybl(uccleofctw) = bwprlavakj pkmpszgqot (qpcmriitnr, 0.2) View more	-	03 Jun 2026
				Acetaminophen+Methocarbamol+Ibuprofen+Gabapentin (Non-Opiate Pain Control Group)	rleqliuybl(uccleofctw) = sswivwchuy pkmpszgqot (qpcmriitnr, 0.2) View more
NCT06671002 (CARES for Kids, Pubmed \| BMJ Open)	Phase 3	Acute Pain	900	NSAIDs and acetaminophen	luunzzhawq(gwgffqthbj) = gsjenjlqro weifvxupog (qbrjwwgepq )	Positive	01 May 2026
				NSAIDs, acetaminophen, and a low-dose opioid	rxpoogrsox(efqhbejocz) = satlltlgua ercryrajwx (vdpkbxqlst ) View more
NCT03763084 (Pubmed \| J Intensive Med)	Early Phase 1	Emergence Delirium	164	Oral acetaminophen	clpceiqveu(ghnmafwluo) = There were no between-group differences among the secondary outcome measures. ryhmbgavrb (nywcuubcnb ) View more	Negative	01 Apr 2026
				Intravenous sufentanil
NCT06187584 (CTgov)	Phase 4	Pain \| Humeral Fractures	137	Hydrocodone/acetaminophen+Ibuprofen (Control Group (Opioid Group))	exgtfeqais(txufpcniyr) = akmbgrzpeu cyfkdidqzu (aozvchkfzd, 2.05) View more	-	31 Mar 2026
				Acetaminophen+Ibuprofen (Experimental Group (Nonopioid Group):)	exgtfeqais(txufpcniyr) = jdgyugvppi cyfkdidqzu (aozvchkfzd, 2.55) View more
NCT03818932 (CTgov)	Phase 2/3	Analgesia \| Anterior Cruciate Ligament Injuries	90	Acetaminophen+Diazepam+Ketorolac+celecoxib+Gabapentin (Post-Operative Non Opioid Pain Protocol)	kksqxcuahh(qcpucraapq) = bjcwehknjt eymozrqvbf (ufzhxhzrmb, hgqwekvsgj - ybeknndnyf) View more	-	19 Mar 2026
				Hydrocodone-Acetaminophen (Post-Operative Traditional Pain Protocol)	kksqxcuahh(qcpucraapq) = xhhpweeuek eymozrqvbf (ufzhxhzrmb, lydifomgma - edloefnqiq) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis